Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof
The invention relates to a method for purifying proteins having a tubulin carboxypeptidase activity from a biological extract, comprising polymerization/depolymerization cycle performed on a biological extract in presence of microtubules. The invention further relates to a peptidic based inhibitor for use in the treatment of a disorder involving altered microtubule detyrosination in an animal, wherein the peptidic based inhibitor comprises a peptidic moiety constituted of 1 to 20 amino acids, said peptidic moiety having an amino acid selected from Y or F at the C-terminal position, and wherein the peptidic based inhibitor inhibits at least partially a tubulin carboxypeptidase activity.
1. A method of treatment of a disorder involving altered microtubule detyrosination in a subject in need thereof comprising administering to the subject in need thereof an amino-acid or peptidic based inhibitor that inhibits, at least partially, a tubulin carboxypeptidase activity, wherein the amino acid or peptidic based inhibitor is selected from the group consisting of:
a Tyr amino-acid (Y) modified with an epoxysuccinyl group, or a peptidic moiety consisting of an amino acid sequence selected from the group consisting of EDY, and EEY, where the tyrosine residue is chemically modified with an epoxysuccinyl group;
a peptidic moiety of 2 to 19 amino acids of the most C-terminal amino acids of SEQ ID NO:12 where the C-terminal position is a tyrosine residue chemically modified with an epoxysuccinyl group; and
a peptidic moiety consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO:17, and SEQ ID NO: 18, where the C-terminal position is a tyrosine residue chemically modified with an epoxysuccinyl group.
2. The method of claim 1 , wherein the amino-acid based inhibitor is Epoxysuccinyl-Y (Eps-Y).
3. The method of claim 1 , wherein the disorder is selected from neurodegenerative diseases, cancers, muscular dystrophies, heart diseases, vascular disorders, infertility, retinal degeneration and ciliopathies.
4. The method of claim 2 , wherein the disorder is selected from neurodegenerative diseases, cancers, muscular dystrophies, heart diseases, vascular disorders, infertility, retinal degeneration and ciliopathies.
5. The method of claim 4 , wherein the neurodegenerative diseases are selected from Alzheimer's disease, Parkinson's disease, psychiatric disorders, and neural disorders, and cancers are selected from colon cancer and neuroblastoma.
6. The method of claim 4 , wherein the neurodegenerative diseases are selected from Alzheimer's disease and neural disorders and cancers are selected from colon cancer and neuroblastoma.